Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer, Solid Tumor
Phase PHASE1
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-M17D1 — Administration by intravenous infusion for a cycle of 3 weeks.

Primary Outcomes

  • Phase Ia: Dose limiting toxicity (DLT) (Up to 21 days after the first dose)
  • Phase Ia: Maximum tolerated dose (MTD) (Up to 21 days after the first dose)
  • Phase Ib: Recommended Phase II Dose (RP2D) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-24
Completion: 2026-08
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Sa Xiao, PHD
15013238943
xiaosa@baili-pharm.com
Qingyuan Zhang
Harbin Medical University Cancer Hospital
Jian Zhang
Fudan University Shanghai Cancer Center
Interventions
  • Drug: BL-M17D1 — Administration by intravenous infusion for a cycle of 3 weeks.
Study Locations (2 sites)
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Sign the informed consent form voluntarily and follow the protocol requirements; 2. Gender is not limited; 3. Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib); 4. Expected survival time ≥3 months; 5. Patients with locally advanced or metastatic HER2-positive/negative breast cancer and other solid tumors; 6. Agree to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years; 7. Must have at least one extracranial measurable lesion that meets the RECIST v1.1 definition; 8. ECOG 0 or 1; 9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0; 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; 11. No blood transfusion is allowed within 14 days before the first use of the study drug, and no cell growth factor is allowed. The organ function level must meet the requirements; 12. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN; 13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment. Exclusion Criteria: 1. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil; 2. History of severe heart disease; 3. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia; 4. Active autoimmune and inflammatory diseases; 5. Other malignancies diagnosed within 5 years before the first dose; 6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded; 7. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg); 8. A history of ILD requiring steroid therapy, or current ILD or radiation pneumonitis of grade ≥1 according to the RTOG/EORTC definition, or a suspicion of such disease; 9. Patients with poor glycemic control; 10. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment; 11. Patients with primary central nervous system tumors or CNS metastases after failure of local treatment; 12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of BL-M17D1's excipients; 13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation; 14. Prior anthracycline therapy with more than the protocol-specified cumulative dose of an anthracycline; 15. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection; 16. Active infection requiring systemic therapy with a serious infection within 4 weeks prior to informed consent; There were indications of pulmonary infection or active pulmonary inflammation within 2 weeks before informed consent; 17. Patients with massive or symptomatic effusions, or poorly controlled effusions; 18. Had participated in another clinical trial within 4 weeks before the first dose; 19. Pregnant or lactating women; 20. Patients with superior vena cava syndrome should not be rehydrated; 21. A history of severe neurological or psychiatric illness; 22. Severe unhealed wounds, ulcers, or fractures within 4 weeks before signing the informed consent; 23. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent; 24. History of intestinal obstruction, inflammatory bowel disease or extensive bowel resection or presence of Crohn's disease, ulcerative colitis or chronic diarrhea; 25. Who are scheduled to receive live vaccine or who receive the vaccine within 28 days before the first dose; 26. The investigators did not consider it appropriate to apply other conditions for participation in the trial.
Conditions Breast Cancer, HER2-positive Breast Canc...
Phase PHASE1, PHASE2
Enrollment 94
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, single-center, exploratory, Phase Ib/II clinical trial evaluating the safety and efficacy of entinostat combined with pyrotinib and endocrine therapy in patients with advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) breast cancer who have failed prior trastuzumab-based therapy. The study consists of two parts: Part I (Phase Ib) employs a 3+3 dose-escalation design to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of entinostat when given in combination with pyrotinib (400 mg daily) and endocrine therapy. Part II (Phase II) uses a Simon two-stage design to further evaluate the efficacy and safety of the combination at the RP2D. The primary efficacy endpoint is progression-free survival (PFS) based on RECIST v1.1. A total of approximately 79-94 participants will be enrolled.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: entinostat — Entinostat is an oral, selective class I histone deacetylase (HDAC) inhibitor, administered at 3 mg, 4 mg, or 5 mg once weekly on Days 1, 8, 15, and 22 of each 28-day cycle, taken 60 minutes after a meal. The dose is determined by the 3+3 dose-escalation design in Part Ib.
  • Drug: Pyrotinib — Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor, administered at a fixed dose of 400 mg once daily, taken 30 minutes after a meal, in each 28-day cycle.
  • Drug: endocrine therapy — Physician-selected endocrine therapy based on patient's prior treatment history and menopausal status. Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg intramuscularly on Days 1, 15, 29, and once monthly thereafter). For premenopausal patients, ovarian function suppression (OFS) with GnRH agonists is added. All endocrine agents are administered according to their approved package inserts.

Primary Outcomes

  • Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), and Recommended Phase II Dose (RP2D) of Entinostat in Combination with Pyrotinib and Endocrine Therapy (Cycle 1 (Day 1 to Day 28))
  • Progression-Free Survival (PFS) (From first dose to disease progression or death, assessed up to 36 months)
  • Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) (From signing of informed consent through 28 days after the last dose of study treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-06-23
Completion: 2027-02
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Collaborators: Taizhou EOC Pharma Co., Ltd.
Contact Information
Study Contact:
Yehui Shi, MD, PhD
+86 18622221183
shiyehui@tjmuch.com
Yehui Shi, MD PhD
+86 23340123
ec_tjcih@126.com
Tianjin Medical University Cancer Institute and Hospital
Interventions
  • Drug: entinostat — Entinostat is an oral, selective class I histone deacetylase (HDAC) inhibitor, administered at 3 mg, 4 mg, or 5 mg once weekly on Days 1, 8, 15, and 22 of each 28-day cycle, taken 60 minutes after a meal. The dose is determined by the 3+3 dose-escalation design in Part Ib.
  • Drug: Pyrotinib — Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor, administered at a fixed dose of 400 mg once daily, taken 30 minutes after a meal, in each 28-day cycle.
  • Drug: endocrine therapy — Physician-selected endocrine therapy based on patient's prior treatment history and menopausal status. Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg intramuscularly on Days 1, 15, 29, and once monthly thereafter). For premenopausal patients, ovarian function suppression (OFS) with GnRH agonists is added. All endocrine agents are administered according to their approved package inserts.
Study Locations (1 sites)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality 300060 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 and ≤ 75 years, female, premenopausal or postmenopausal. 2. Histologically confirmed HR+/HER2+ breast cancer (HER2 positive defined as IHC 3+ or FISH confirmed by the pathology department of the study center). 3. Histologically confirmed locally advanced breast cancer (not amenable to curative local therapy) or recurrent/metastatic breast cancer. 4. Prior treatment with trastuzumab and taxane-based anticancer therapy. 5. Received 1-2 prior lines of systemic anticancer therapy in the advanced setting. 6. Life expectancy ≥ 3 months. 7. At least one measurable lesion per RECIST v1.1. 8. ECOG performance status 0-2. 9. All acute toxicities from prior anticancer therapy resolved to Grade 0-1 (per NCI CTCAE v5.0), except alopecia and toxicities deemed by the investigator to pose no safety risk. 10. Adequate bone marrow function: ANC ≥ 1.5×10\^9/L, platelet ≥ 100×10\^9/L, hemoglobin ≥ 90 g/L. 11. Adequate hepatic and renal function: TBIL ≤ 1.5×ULN; ALT and AST ≤ 2.5×ULN (or ≤ 5×ULN in the presence of liver metastases); BUN and Cr ≤ 1.5×ULN with creatinine clearance ≥ 50 mL/min. 12. Voluntarily participate and sign written informed consent. - Exclusion Criteria: 1. Factors significantly affecting oral drug absorption, such as inability to swallow, chronic diarrhea, or intestinal obstruction. 2. Prior treatment with any HDAC inhibitor for antitumor therapy. 3. Prior or current use of any HER2-targeted tyrosine kinase inhibitor (including lapatinib, neratinib, pyrotinib, etc.). 4. Known allergy to any component of the study drugs. 5. Other malignancy within 5 years prior to enrollment, except cured papillary thyroid carcinoma, cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin. 6. Participation in another drug clinical trial within 4 weeks prior to enrollment. 7. History of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency diseases, or history of organ transplantation. 8. Uncontrolled significant cardiovascular disease: clinically significant QTc interval prolongation or QTc \> 450 ms at screening; severe cardiac impairment (NYHA \> Class II); unstable angina or myocardial infarction within 6 months; or severe arrhythmia. 9. Pregnant or lactating women, or positive pregnancy test at baseline; or women of childbearing potential who are unwilling to use effective contraception during the study and for at least 8 weeks after the last dose. 10. Concomitant diseases that, in the investigator's judgment, could seriously endanger patient safety or affect study completion (e.g., severe hypertension, diabetes, thyroid disease, active infection). 11. Known history of neurological or psychiatric disorders, including epilepsy or dementia. 12. Active hepatitis (HBV: HBsAg positive with HBV DNA ≥ 500 IU/mL; HCV: HCV antibody positive with HCV RNA \> ULN). 13. Any condition that, in the investigator's judgment, makes the patient unsuitable for study participation. \-
Conditions HER2-positive Breast Cancer
Phase PHASE2
Enrollment 182
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of pyrotinib and trastuzumab combined with pegylated liposomal doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel for injection albumin bound as neoadjuvant therapy in patients with early HER2-positive breast cancer. Eligible patients will receive 8 cycles of neoadjuvant treatment. Pyrotinib will be administered orally once daily, and trastuzumab will be administered intravenously every 3 weeks. During the first 4 cycles, patients will receive pegylated liposomal doxorubicin hydrochloride and cyclophosphamide. During the subsequent 4 cycles, patients will receive paclitaxel for injection albumin bound. The primary outcome is total pathological complete response rate. Secondary outcomes include breast pathological complete response rate, lymph node pathological complete response rate, objective response rate, event-free survival, distant disease-free survival, overall survival, and safety.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib Maleate — Pyrotinib maleate will be administered orally at 400 mg once daily from Day 1 of Cycle 1. It should be taken within 30 minutes after breakfast and continued throughout the neoadjuvant treatment period.
  • Drug: Trastuzumab (H, 8mg/kg — Trastuzumab will be administered intravenously at a loading dose of 8 mg/kg on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each subsequent 3-week cycle during neoadjuvant treatment.
  • Drug: pegylated liposomal doxorubicin hydrochloride — Pegylated liposomal doxorubicin hydrochloride will be administered intravenously at 35 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment.
  • Drug: Cyclophosphamide — Cyclophosphamide will be administered intravenously at 600 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment in combination with pegylated liposomal doxorubicin hydrochloride, pyrotinib, and trastuzumab.
  • Drug: Paclitaxel for Injection Albumin Bound — Paclitaxel for injection albumin bound will be administered intravenously at 230-260 mg/m² on Day 1 of each 3-week cycle for the subsequent 4 cycles of neoadjuvant treatment in combination with pyrotinib and trastuzumab.

Primary Outcomes

  • Total Pathological Complete Response Rate (At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-30
Completion: 2029-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 182 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hebei Medical University Fourth Hospital
Principal Investigators:
  • Zhenchuan Song (PRINCIPAL_INVESTIGATOR) - Hebei Medical University Fourth Hospital
Contact Information
Study Contact:
Zhenchuan Song, MD
18531117857
songzhch@hotmail.com
Lina Zhang, MD
+86 185 3111 7825
Zhenchuan Song, MD
185 31117857
songzhch@hotmail.com
The Fourth Hospital of Hebei Medical University
Interventions
  • Drug: Pyrotinib Maleate — Pyrotinib maleate will be administered orally at 400 mg once daily from Day 1 of Cycle 1. It should be taken within 30 minutes after breakfast and continued throughout the neoadjuvant treatment period.
  • Drug: Trastuzumab (H, 8mg/kg — Trastuzumab will be administered intravenously at a loading dose of 8 mg/kg on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each subsequent 3-week cycle during neoadjuvant treatment.
  • Drug: pegylated liposomal doxorubicin hydrochloride — Pegylated liposomal doxorubicin hydrochloride will be administered intravenously at 35 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment.
  • Drug: Cyclophosphamide — Cyclophosphamide will be administered intravenously at 600 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment in combination with pegylated liposomal doxorubicin hydrochloride, pyrotinib, and trastuzumab.
  • Drug: Paclitaxel for Injection Albumin Bound — Paclitaxel for injection albumin bound will be administered intravenously at 230-260 mg/m² on Day 1 of each 3-week cycle for the subsequent 4 cycles of neoadjuvant treatment in combination with pyrotinib and trastuzumab.
Study Locations (1 sites)
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 65 years. * Patients with previously untreated invasive breast cancer confirmed by pathological examination. * HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status. * Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. * At least one measurable lesion according to RECIST version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function, meeting all of the following criteria: * Hemoglobin ≥100 g/L. * Absolute neutrophil count ≥1.5 × 10\^9/L. * Platelet count ≥100 × 10\^9/L. * Total bilirubin ≤1 × upper limit of normal (ULN). * Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN. * Alkaline phosphatase ≤2.5 × ULN. * Blood urea nitrogen and serum creatinine ≤1.5 × ULN. * Left ventricular ejection fraction ≥55% by echocardiography. * Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate contraception during the study and for 8 weeks after the last dose of study treatment. * Patients must voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up. Exclusion Criteria: * Prior receipt of any anti-tumor therapy, including chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy. * Concurrent receipt of any other anti-tumor therapy. * Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer. * Stage IV breast cancer. * Breast cancer not confirmed by pathological examination. * History of other malignancies within 5 years, except cured carcinoma in situ of the cervix. * Severe dysfunction of major organs, including the heart, liver, or kidney. * Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that may affect drug administration or absorption. * Participation in another drug clinical trial within 4 weeks before enrollment. * Known history of allergy to any component of the study treatment. * History of immunodeficiency, including positive HIV test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation. * History of any cardiac disease, including clinically significant arrhythmia requiring medication, myocardial infarction, heart failure, or any other cardiac disease judged by the investigator to make the patient unsuitable for this study. * Pregnant or breastfeeding women, women of childbearing potential with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective contraception throughout the study. * Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or affect completion of the study, including but not limited to uncontrolled severe hypertension, severe diabetes mellitus, or active infection. * Clear history of neurological or psychiatric disorders, including epilepsy or dementia. * Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.
Conditions Inoperable, Locally Advanced or Metastat...
Phase PHASE1, PHASE2
Enrollment 316
Locations 32 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER+, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib, or neratinib). Cohort 3 will focus on inoperable, locally advanced or metastatic, ER+, HER2-negative, PIK3CA-mutated breast cancer with resistance to adjuvant endocrine therapy.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Giredestrant — 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
  • Drug: Abemaciclib — 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
  • Drug: Ipatasertib — 400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: Inavolisib — 9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: Ribociclib — 600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: Everolimus — 10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: Samuraciclib — 360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: PH FDC SC — On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

Primary Outcomes

  • Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) (From Baseline until disease progression (up to 6 years))
  • Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) (From Baseline until 30 days after the last dose of study drug (up to 6 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-06-22
Completion: 2029-05-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 316 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: CO42867 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: Giredestrant — 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
  • Drug: Abemaciclib — 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
  • Drug: Ipatasertib — 400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: Inavolisib — 9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
  • Drug: Ribociclib — 600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Study Locations (32 sites)
City of Hope, Duarte, California 91010 United States
City of Hope - Orange County Lennar Foundation Cancer Center, Irvine, California 92618-2377 United States
University of California, San Francisco (UCSF), San Francisco, California 94143 United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Santa Monica, California 90404 United States
Stanford Cancer Institute (SCI), Stanford, California 94305 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey 07728 United States
Regional Cancer Care Associates LLC ? Howell Division, Howell Township, New Jersey 07731 United States
Levine Cancer Institute, Charlotte, North Carolina 28204 United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria for Cohort 1 (Stage 1 \[and Stage 2, only where indicated\]): * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Documented estrogen receptor-positive (ER+) tumor * Patients for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines * Radiologic/objective evidence of recurrence or progression after the most recent systemic therapy for breast cancer * Disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease (note: at least one line of therapy must have contained a CDK4/6i administered for a minimum of 8 weeks prior to disease progression.) * Postmenopausal status for women * Life expectancy ≥3 months * Availability of a representative tumor specimen that is suitable for biomarker evaluation via central testing * Prior fulvestrant therapy is allowed * Stages 1 and 2: Measurable disease (at least one target lesion) according to RECIST v1.1 * Stages 1 and 2: Adequate hematologic and end-organ function * Stages 1 and 2: Stable anticoagulant regimen for patients receiving therapeutic anticoagulation Inclusion Criteria for Cohort 2 (Stage 1 \[and Stage 2, only where indicated\]): * ECOG Performance Status of 0 or 1 * Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection * ER+, HER2-positive breast cancer * Postmenopausal status for women * Life expectancy ≥3 months * Willingness to have a representative tumor specimen that is suitable for biomarker evaluation via central testing submitted, if available * Prior endocrine therapy in the advanced setting allowed, including fulvestrant if given more than 28 days prior to randomization, but excluding other selective estrogen receptor degraders (SERDs) * Stages 1 and 2: Measurable disease (at least one target lesion) according to RECIST v1.1 * Stages 1 and 2: Baseline left ventricular ejection fraction (LVEF) ≥50% as measured by ECHO or MUGA scans * Stages 1 and 2: Adequate hematologic and end-organ function * Stages 1 and 2: Stable anticoagulant regimen for patients receiving therapeutic anticoagulation Inclusion Criteria for Cohorts 1 and 2 (Stage 2): * Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator, provided that a Stage 2 slot is available and patient meets eligibility criteria for Stage 2 * Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1 because of unacceptable toxicity to drugs, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator Inclusion Criteria for Cohort 3: * Measurable disease (at least one target lesion) according to RECIST v1.1 * ECOG Performance Status of 0 or 1 * Documented ER+ tumor * Patients for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines * Histologically or cytologically confirmed and documented adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent * Patients must have progressed during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen. If a CDK4/6i was included as part of neoadjuvant or adjuvant therapy, progression event must be \>12 months since completion of CDK4/6i portion of neoadjuvant or adjuvant therapy. * Postmenopausal status for women (including women on or starting luteinizing hormone-releasing hormone \[LHRH\] agonist for ovarian suppression prior to randomization) * Life expectancy ≥6 months * Adequate hematologic and end-organ function * Evidence of an eligible PIK3CA mutation based on pre-existing test results (i.e., previously obtained as part of clinical practice) from blood or tumor tissue. If pre-existing test results are not available, submission of a freshly collected pretreatment blood sample to determine PIK3CA mutation status at a central testing site with the FoundationOne Liquid® CDx assay is required. Exclusion Criteria: General Exclusion Criteria for all Treatment Arms in Stage 1, Cohorts 1 and 2 (unless only applicable to one cohort, as indicated): * Prior treatment with any of the protocol-specified study treatments * Treatment with investigational therapy within 28 days prior to initiation of study treatment * Systemic treatment for breast cancer within 2 weeks of Cycle 1, Day 1 or 5 half-lives of the drug prior to Cycle 1, Day 1 * Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 or better, with the exception of alopecia of any grade and Grade ≤2 peripheral neuropathy * Eligible only for the control arm * Prior allogeneic stem cell or solid organ transplantation * Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study * History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures * Uncontrolled tumor-related pain * Uncontrolled or symptomatic hypercalcemia * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * History of leptomeningeal disease * Active tuberculosis * Severe infection within 4 weeks prior to initiation of study treatment * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan * Active cardiac disease or history of cardiac dysfunction * Positive HIV test at screening or at any time prior to screening * Active Hepatitis B or Hepatitis C virus infection * Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery, including gastric resection, potentially affecting enteral absorption * Known allergy or hypersensitivity to any of the study drugs or any of their excipients * Cohort 1 only: Known HER2-positive breast cancer * Cohort 1 only: Concurrent hormone replacement therapy * Cohort 1 only: Prior treatment with cytotoxic chemotherapy for metastatic breast cancer (with the exception of single agent capecitabine, which will count as a single line of therapy) * Cohort 2 only: Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy * Cohort 2 only: Current chronic daily treatment (continuous for \>3 months) with corticosteroids (dose of 10 mg/day methylprednisolone equivalent), excluding inhaled steroids Additional Exclusion Criteria for Giredestrant + Abemaciclib Arm and Giredestrant + Abemaciclib + Atezolizumab Arm (Cohort 1, Stage 1): * Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy * History of major surgical resection involving the stomach or small bowel, or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea * History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest Addi
Conditions Hormone Receptor-positive Metastatic Bre...
Phase PHASE4
Enrollment 300
Locations 54 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The MINERVA Trial aims to evaluate safety, efficacy and quality of life (QoL) for the combination of Abemaciclib with an Aromatase Inhibitor or Fulvestrant in pre- and postmenopausal patients with metastatic hormone receptor positive HER2 negative breast cancer in the first line setting. Side effect monitoring and patient reported outcomes will be captured using the web- and app-based CANKADO digital health application. Via this user-friendly tool the patients can document their therapy side effects (e.g. diarrhea) and outcomes on a day-to-day basis. The capturing of side effects using the digital health application will be done additionally to the regular AE documentation. Furthermore, translational research objectives of this trial include the investigation of biomarkers (ct-DNA, germline DNA) to evaluate whether they can give insights into the reasons for response, intrinsic or acquired resistance to the combined endocrine

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib + Aromatase Inhibitor — Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
  • Drug: Abemaciclib + Fulvestrant — Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)

Primary Outcomes

  • Progression Free Survival (PFS) (Time from date of trial registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-04-27
Completion: 2029-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prof. Wolfgang Janni
Collaborators: Eli Lilly and Company
Principal Investigators:
  • Brigitte Rack, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - Department of Gynecology and Obstetrics, University Hospital Ulm, Germany
Contact Information
Study Contact:
Natalie Uhl
+49 731 500 58652
natalie.uhl@uniklinik-ulm.de
Interventions
  • Drug: Abemaciclib + Aromatase Inhibitor — Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
  • Drug: Abemaciclib + Fulvestrant — Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
Study Locations (54 sites)
Kliniken Ostalb gkAöR, Aalen, Germany
Klinikum St. Marien Kommunalunternehmen - AöR Der Stadt Amberg, Amberg, Germany
Klinikum Aschaffenburg-Alzenau gGmbH, Aschaffenburg, Germany
Gemeinschaftspraxis Dr. Heinrich / Dr. Bangerter, Augsburg, Germany
Universitätsklinikum Augsburg A.d.ö.R, Augsburg, Germany
MediOnko-Institut GbR, Berlin, Germany
Hämatologikum Biberach, Biberach, Germany
Gynäkologisches Zentrum Bonn - Friedensplatz, Bonn, Germany
Studien GbR Braunschweig, Braunschweig, Germany
Hämato-Onkologische Praxis im Medicum, Bremen, Germany
Eligibility Criteria
Inclusion Criteria: Patients will be included in the trial only if they meet all the following criteria: 1. Have given written informed consent prior to any trial-specific procedures 2. Are reliable, willing to be available for the duration of the trial and are willing to follow trial procedures 3. Are female and aged ≥ 18 years 4. Diagnosis of hormone receptor positive (HR+), HER2- breast cancer. Although not required as a protocol procedure, metastatic disease should be considered for biopsy whenever possible to reassess HR and HER2 status if clinically indicated. 5. To fulfill the requirement for HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (estrogen receptor \[ER\], progesterone receptor \[PgR\]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010). 6. To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization (ISH) as defined in the relevant ASCO/CAP guidelines (Wolff et al. 2013). 7. Have locally advanced recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease 8. Indication for endocrine based therapy in the metastatic setting 9. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale 10. If central nervous system (CNS) metastases are known these have to be stable (radiotherapy finished for more than 14 days ago, no required steroid medication with more than 4 mg Dexamethasone per day) 11. Pre- and postmenopausal patients are allowed. Postmenopausal is defined as no menses for 12 months without an alternative medical cause. Women of Childbearing Potential (WOCBP, defined as not postmenopausal and not surgically or congenitally sterile) whose male partners are potentially fertile (e.g. no vasectomy) must use highly effective contraception methods for the duration of the trial and for at least 3 weeks after last dose of drugs used in the trial.Women of childbearing potential must use highly effective contraception methods for two years after the last dose of fulvestrant. Highly effective birth control methods that results in a failure rate of less than 1% per year include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner. Sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the patient. 12. No prior therapy for metastatic disease (except for first line endocrine therapy for maximal 3 months prior to start of abemaciclib therapy and if no progress occurred before study entry) 13. Previous adjuvant endocrine therapy and (neo)adjuvant chemotherapy is allowed 14. Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or ≤ Grade 2 peripheral neuropathy prior to registration. A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy). 15. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration. 16. One of the following as defined by the RECIST v1. 1 (see Attachment 15.5): 1. Measurable disease. At least one measurable lesion assessable using standard techniques by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1). Tumor evaluation according to RECIST version 1.1 (based on local assessment) has to be performed within 28 days before trial registration. 2. Nonmeasurable bone-only disease (must be evaluable, but not necessarily measurable by RECIST). Nonmeasurable bone-only disease may include any of the following: blastic bone lesion, lytic bone lesions without a measurable soft tissue component, or mixed lytic-blastic bone lesions without a measurable soft tissue component. 17. The patient has adequate bone marrow and organ function evidenced by the following laboratory results: absolute neutrophil count (ANC) ≥ 1.5 × 109/L, Platelet count ≥ 100 × 109/L, Hemoglobin ≥ 8 g/dL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 × ULN (≤ 3 x ULN in case of liver metastases), Total Bilirubin ≤ 1.5 × ULN (with Gilbert's syndrome max. 2 x ULN), Serum Creatinine ≤ 2.0 mg/dl or 177µmol/L, Coagulation: International Normalized Ratio (INR) ≤ 1,5 18. The patient is able to swallow oral medications 19. Willingness to use the provided CANKADO digital health application to report side effects and patient reported outcomes (The use of the CANKADO app is not mandatory for study participation, but is strongly recommended) 20. Negative pregnancy test before trial registration for women of child-bearing potential and highly effective contraception if the risk of conception exists and a negative serum pregnancy test within 7 days after the first dose of trial treatment. Pregnancy tests should be performed in premenopausal patients according to local standard Exclusion Criteria: Patients will be included in the trial only if they meet none of the following criteria: 1. Visceral crisis or life expectancy \< 6 months 2. History of hypersensitivity reactions attributed to Abemaciclib or to other components of drug formulation 3. Prior treatment with chemotherapy in the metastatic setting or endocrine therapy in the metastatic setting (except for first line endocrine therapy in metastatic or locally advanced disease for maximal 3 months prior to start of abemaciclib therapy and if no progress occurred before study entry) 4. Patient not eligible for endocrine based therapy 5. Any concurrent severe, uncontrolled systemic disease, social or psychiatric condition that might interfere with the planned treatment and with the patient's adherence to the protocol 6. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this trial (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 7. Prior treatment with a CDK4/6 inhibitor for metastatic or locally advanced disease (first-line treatment with a CDK 4/6 inhibitor (Ribociclib/Palbociclib) in the metastatic setting is allowed only if terminated due to toxicity after max 3 months and no progression occurred before study entry. Prior treatment with a CDK 4/6 inhibitor in the neo-/adjuvant setting is allowed.) 8. 8\. Treatment with any other investigational agents within four weeks or 5 half-lives prior to trial registration, whichever is longer 9. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. 10. Females who are pregnant or lactating 11. Legal incapacity or limited
Conditions Breast Cancer Susceptibility Gene (BRCA1...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1/2 genetic mutation will reduce their levels of fear of cancer recurrence. The main questions this study aims to answer are: * Will the women who have received the adapted CBT be satisfied with it? * Will there be a significant difference in the women's fear of cancer recurrence and other variables (e.g., depression, anxiety, insomnia, fatigue, quality of life) between the comparison groups? * Will the effects of the adapted CBT hold over time? * What are the roles of different etiological mediating variables in the relationship between fear of cancer recurrence and the effects of the adapted CBT on the severity of fear of cancer recurrence? Researchers will compare the effects of the adapted CBT between the immediate condition and the waitlist condition. Participants will be: * Either placed in the immediate condition or the waitlist condition (the participants in the waitlist condition will begin their therapy once the immediate group is done with theirs). * Taking part in a group CBT session online once a week for eleven weeks. * Completing questionnaires pre-intervention, post-intervention, 3 months post-intervention, and 6 months post-intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive-behavioral group therapy — The intervention consists of a 4-week cognitive-behavioral group therapy. Each session is given online and will last 90-minutes. The intervention has been adapted to the population of women with a cancer and a BRCA1/2 mutation from a behavioral-cognitive therapy for fear of cancer recurrence that already exists and has already been proven effective.

Primary Outcomes

  • Fear of cancer recurrence inventory (FCRI) (At recruitment, 4 weeks after recruitment, 3 and 6 months post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Quebec-Universite Laval
Contact Information
Study Contact:
Emma Coughlan
418-525-4444
emma.coughlan@crchudequebec.ulaval.ca
Interventions
  • Behavioral: Cognitive-behavioral group therapy — The intervention consists of a 4-week cognitive-behavioral group therapy. Each session is given online and will last 90-minutes. The intervention has been adapted to the population of women with a cancer and a BRCA1/2 mutation from a behavioral-cognitive therapy for fear of cancer recurrence that already exists and has already been proven effective.
Study Locations (1 sites)
CHU de Québec-Université Laval, Québec, Quebec Canada
Eligibility Criteria
Inclusion Criteria: * 1\) Have completed primary treatment for breast or ovarian cancer (i.e., surgery, chemotherapy, and radiotherapy). * 2\) Be known to carry a BRCA1/2 pathogenic mutation. * 3\) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subscale. * 4\) Be at least 18 years of age. * 5\) Be able to read, understand and express herself in French. Exclusion Criteria: * 1\) Have distant metastases (in the case of ovarian cancer, only stages IV and IIIC will be excluded). * 2\) Be known to carry a BRCA1/2 "VUS" mutation. * 3\) Have a known cognitive disorder. * 4\) Have a known severe psychological disorder (e.g., psychotic disorder, bipolar disorder, substance abuse or dependence disorder). * 5\) Have already taken part in the original FCR group psychotherapy at the CHU de Québec. * 6\) Women taking psychotropic medication are eligible, but only if the dosage has been stable for at least one month.
Conditions Bioequivalence
Phase PHASE1
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this study is to evaluate the bioequivalence of paclitaxel protein-bound particles for injectable suspension (albumin-bound) (100 mg, test product) and Abraxane® (100 mg, reference product) in breast cancer patients.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) — IV infusion, 260 mg/m\^2
  • Drug: Abraxane® — IV infusion, 260 mg/m\^2

Primary Outcomes

  • Peak Plasma Concentration (Cmax) (72 hours)
  • Area under the plasma concentration versus time curve AUC0-t (72 hours)
  • Area under the plasma concentration versus time curve AUC0-∞ (72 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-06-26
Completion: 2026-02-25
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Contact Information
Study Contact:
Clinical Trials Information Group officer
86-0311-69085587
ctr-contact@cspc.cn
Yanhua Ding, Medicine Doctor
0431-88782168
dingyanhua2003@126.com
The First Hospital of Jilin University
Interventions
  • Drug: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) — IV infusion, 260 mg/m\^2
  • Drug: Abraxane® — IV infusion, 260 mg/m\^2
Study Locations (1 sites)
The First Hospital of Jilin University, Changchun, Jilin 130021 China
Eligibility Criteria
Inclusion Criteria: * 1\) Subjects fully understand the purpose, nature, method and possible adverse reactions of the study, volunteer as subjects, and sign informed consent prior to the commencement of any study procedure; * 2\) Male and female, ages 18-75 years both inclusive; * 3\) Subjects with breast cancer confirmed by histopathology and/or cytology who meet one of the following conditions: ①Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated; ②This treatment criteria (NCCN guidelines and CSCO guidelines - Breast cancer) is used to determine whether the subjects are suitable for paclitaxel for injection (albumin-bound) monotherapy. ③Subjects received standard treatment without conditions and were judged to benefit from injectable paclitaxel (albumin-binding) monotherapy; * 4\) ECOG Score ≤ 2 points; * 5\) The expecting life span ≥ 3months; * 6\) The results of blood, liver and kidney function tests are within the following ranges: Absolute neutrophil counts (ANC) ≥ 1.5×10\^9/L Platelets (PLT) ≥ 100×10\^9/L Hemoglobin (Hb) ≥ 90 g/L Total bilirubin (TBIL) ≤ 1.5×ULN Alanine transaminase (ALT), Aspartate aminotransferase (AST)≤×ULN (for patients with liver metastasis, ≤ 5×ULN) Creatinine clearance (CrCL)≥ 60 mL/min * 7\) The subject has no fertility plan (including sperm donation and egg donation) for at least 6 months from the signing of informed consent to the last dose and voluntarily takes non-drug effective contraceptive measures; * 8\) Subjects can communicate well with the investigators, understand and comply with the requirements of the study. Exclusion Criteria: * 1\) A severe allergy or hypersensitivity to paclitaxel or human albumin; * 2\) In addition to cancer, have any other serious liver, kidney/genitourinary, gastrointestinal (e.g., abdominal inflammation), cardiovascular (e.g., congestive heart failure, ventricular arrhythmia, myocardial infarction, unstable angina), cerebrovascular, pulmonary (e.g., interstitial lung disease), endocrine, immune, musculoskeletal, neurological, psychiatric, skin, or blood (e.g., bleeding diathymia or clotting disorders) diseases Patients with a known or present history of the disease who are deemed unsuitable for enrollment by the investigators; * 3\) Those who had undergone major surgery within 4 weeks prior to screening, or planned to undergo major surgery during the study period; * 4\) Pregnant or lactating female subjects; * 5\) Hepatitis B surface antigen positive and HBV DNA positive; HCV core antibody positive and HCV RNA positive; HIV antigen/antibody positive; treponema pallidum antibody positive and rapid plasma reaction hormone (RPR) positive; * 6\) Those who used chemical small molecule anti-tumor drugs (including endocrine therapy), biological macromolecular anti-tumor drugs, biological therapy, radiotherapy or needed to combine other anti-tumor drugs for treatment during the study period within 4 weeks before the first dose; * 7\) Electrocardiogram shows significant abnormality, and/or baseline QTcF interval is \> 470 ms; * 8\) Pre-screening sensory neuropathy/peripheral neuropathy are ≥ grade 2; * 9\) Blood donation or significant blood loss (\> 400 mL) within 90 days before - screening; * 10\) Ingestion of an inhibitor or inducer of CYP2C8 or CYP3A4 within 28 days prior to dosing (acceptable drug use is stable in homeostasis, that is, the dosing regimen remains unchanged; However, the use of moderate-strong inhibitory agents/moderate-strong inducers should be prohibited), or drugs (including Chinese herbs) that can affect the absorption, distribution, metabolism and excretion behavior of the study drugs or special diets (such as products containing caffeine or xanthine, grapefruit fruits and products containing grapefruit ingredients, etc.); * 11\) Those who consumed more than 14 units of alcohol per week in the 3 months before screening (1 unit ≈ 360 mL for beer, or 45 mL for spirits, or 150 mL for wine) or who could not stop drinking during the study period or who are breath-positive for alcohol; * 12\) Smoking \> 5 cigarettes per day within 3 months prior to screening or smoking cannot be stopped during the study period; * 13\) Any clinically significant abnormal results in the subjects' vital signs, physical examination, clinical laboratory examination (unless otherwise specified in the protocol), 12-lead electrocardiogram (ECG) and other examination results that the investigator deems unsuitable for enrollment; * 14\) Within 6 months prior to screening, there is a history of drug abuse (except regular use of pain medications due to cancer pain) or positive drug abuse screening; * 15\) Toxicity caused by using of anti-tumor drugs prior to enrolment do not return to ≤ grade 1 or baseline levels, except for alopecia; * 16\) Subjects receiving granulocyte-stimulating growth factor treatment within 2 weeks before dosing; * 17\) Subjects who have participated in any clinical trial within 1 month before screening (start from the time of the last dose); * 18\) Any other circumstances determined by the investigator to be inappropriate are not suitable for participation in this study
Conditions Treatment Adherence
Phase NA
Enrollment 159
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Background: Hormonal therapy (HT) is highly effective for nearly all breast cancer patients with hormone receptor-positive tumors, which are about 80% of all breast cancer diagnoses. Long-term use of HT reduces cancer recurrence rates and cuts the risk of mortality nearly in half during the second decade after diagnosis. Despite proven benefits, 33% of women who are prescribed HT do not take it as prescribed (\<80% take their daily dosage). Latina patients are disproportionately affected by non-medical drivers of health (NMDoH) that keep them from adhering to HT and are at higher risk of breast cancer recurrence and mortality. Objective: The goal of this 4-year randomized controlled study is to assess the effectiveness of the bilingual, culturally tailored, interactive HT Helper App, in combination with patient navigation (PN), on improving adherence to HT among Latina breast cancer patients experiencing any NMDoH barriers, such as income, health insurance, education, health literacy, and language, that impact their medication adherence. This theory-based intervention will increase patient education, enhance self-efficacy, facilitate communication with the medical team and coordination of resources to address NMDoH barriers, and help patients develop self-care skills for optimal adherence to HT, ensuring patients the most equitable treatment outcomes possible, including improvement in quality of life, survival, and life expectancy. Specific Aims/Hypothesis: 1) Conduct a 3-group randomized study to assess the effectiveness of the HT Helper App + PN vs. PN alone vs. usual care, on HT adherence; and 2) Assess the effect of each study condition on patient self-efficacy to identify side effects, use self-care to manage side effects, and communicate with the medical team. We hypothesize that the HT Helper App + PN and the PN alone groups will have greater rates of HT adherence and higher patient self-efficacy than the usual care group; with the HT Helper App + PN achieving better results than both PN alone and the usual care groups. Study Design. The proposed study involves a parallel 3-group randomized controlled trial with 5-time assessments (baseline, 3, 6, 12, and 18 months) and will enroll 159 breast cancer patients who are prescribed HT and are attending the breast clinic at the Mays Cancer Center at UT Health San Antonio. Intervention components are based on Social Cognitive Theory and elements of Motivational Interviewing. Cancer Relevance. This innovative multi-level intervention will improve adherence to HT by addressing NMDoH and promote equitable breast cancer outcomes, including reduced recurrence and improved quality of life, overall survival, and life expectancy among underserved Latina patients. The anticipated outcome is a scalable, evidence-based, and easily disseminated intervention with potentially broad use to patients using oral anticancer medications.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: HT Helper app use plus patient navigation support — HT Helper app plus patient navigation support to promote hormone therapy adherence among breast cancer patients experiencing NMDoH barriers
  • Behavioral: Patient Navigation support alone — Patient navigation support to address NMDoH barriers impacting hormone therapy adherence
  • Other: Usual Care — Usual care provided to patients who are prescribed hormone therapy and attend the Breast Clinic at the Mays Cancer Center

Primary Outcomes

  • Adherence to hormone therapy (From enrollment to end of the intervention at 18 months)
  • Self-efficacy for Appropriate Medication Use Scale (SEAMS) (From enrollment to the end of the intervention at 18 months)
  • Social support (From enrollment to the end of the intervention at 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-26
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 159 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Principal Investigators:
  • Patricia Chalela, DrPH, MPH (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Study Coordinator
210-567-6523
HTHelper@uthscsa.edu
Research Assistant
210-567-6523
HTHelper@uthscsa.edu
Patricia Chalela, DrPH
210-562-6513
chalela@uthscsa.edu
The University of Texas Health Science Center at San Antonio
Interventions
  • Behavioral: HT Helper app use plus patient navigation support — HT Helper app plus patient navigation support to promote hormone therapy adherence among breast cancer patients experiencing NMDoH barriers
  • Behavioral: Patient Navigation support alone — Patient navigation support to address NMDoH barriers impacting hormone therapy adherence
  • Other: Usual Care — Usual care provided to patients who are prescribed hormone therapy and attend the Breast Clinic at the Mays Cancer Center
Study Locations (1 sites)
The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: English- or Spanish-speaking Latina patients aged 18 and older who: a) are diagnosed with hormone receptor-positive breast cancer and prescribed HT; b) within 1 to 24 months of starting HT; c) are experiencing any NMDoH by the Avanzando Center NMDoH Screener; d) are able to read; e) own a smartphone and are able to send and receive text messages and access the Internet; and f) are able to provide informed consent to participate in the study. Exclusion Criteria: Not meeting the criteria above, or patients who: a) are not Latina and are younger than 18 years; b) are not receiving HT treatment; c) with more than 24 months of starting treatment; d) do not experience any NMDoH by the Avanzando Center NMDoH Screener; e) are unable to read; f) do not own a smartphone and are unable to send and receive text messages and access the Internet; g) are unable to respond to text messages and questions or unable to download the study app; h) are unable to provide informed consent due to a mental, emotional, or physical handicap that keeps them from understanding the consent information; i) are unable to see the app and study materials and videos (i.e., are blind, deaf); and j) currently participating in a psychosocial intervention trial or individual/group psychotherapy.
Conditions Breast Cancer Metastatic, Treatment Outc...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 negative Breast Cancer Patients

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Primary Outcomes

  • PFS (Six months after the last patient was enrolled)
  • ORR (Up to approximately 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-05
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Jian Zhang, MD,PhD (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Jian Zhang, MD,PhD
+8664175590
syner2000@163.com
Jian Zhang, MD,PhD
+8664175590
syner2000@163.com
Fudan University Shanghai Cancer Center
Interventions
N/A
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged 18 or above; 2. The Eastern Cooperative Oncology Group (ECOG) physical condition score of the United States is ≤2; 3. Unresectable or metastatic triple-negative breast cancer confirmed by tumor histology or cytology, and having received at least two systemic treatments previously (at least one of which was for metastatic disease); Or HR+/HER2- (IHC 0, 1+ or IHC 2+/ISH-) unresectable or metastatic breast cancer confirmed by tumor histology or cytology, with previous endocrine therapy and ≥2 lines of systemic therapy (for metastatic disease); 4. Receive gosatetuzumab treatment in the advanced stage; 5. During the study period, voluntarily abide by this trial protocol and receive regular follow-ups; 6. All women of childbearing age, fertile men or their spouses who have no plans for fertility or sperm donation throughout the trial period until 6 months after the last dose, or who voluntarily take effective contraceptive measures. Exclusion Criteria: 1. Pregnant or lactating women; 2. Those with acute or chronic infections, or those with other serious diseases at the same time, are judged by the researchers as unsuitable for this study; 3. Having suffered from other malignant tumors within 5 years (excluding the following situations: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma; A second primary cancer that has been completely cured and has no recurrence within five years; Researchers have clearly identified which primary tumor source the metastatic foci belong to. 4. Those with mental illness or mental disorders, poor compliance and inability to cooperate and describe treatment responses; 5. Those with severe organic diseases or major organ failure, such as decompensated heart, lung, liver or kidney failure, which makes them unable to tolerate treatment; 6. Patients allergic to gosatetuzumab; 7. Patients who changed their treatment regimens after gosatetuzumab treatment due to non-disease progression reasons; 8. The researcher believes that the patient has other circumstances that make them unsuitable for participating in this study.
Conditions Prostate Cancer, Liver Cancer, Breast Ca...
Phase Not Applicable
Enrollment 750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene therapy. The genes expressed by poxviral vectors do not become part of the genetic material left behind. Because gene therapy is a somewhat new technology, a prolonged monitoring of patients' health status is necessary, according to new specific reporting requirements for harmful events in patients who undergo such gene therapy studies. The risk of any long-term negative effects from the gene therapy that patients had received is quite small. Still, it is important that there be updates at least annually. This annual monitoring of health status will extend for 15 years, according to guidelines from the Food and Drug Administration, or for as long as patients are willing to participate. Patients who received poxviral vectors (vaccinia or fowlpox, or both) at the National Cancer Institute, through a trial affiliated with the Laboratory of Tumor Immunology and Biology, may be eligible for this study. Participants will be involved in the following forms of data collection: * Annual medical history and physical examinations for the first 5 years following the last vaccine. * Annual telephone contact during the last 10 years. * Health status check, including primary cancer status, secondary malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders. * Blood tests for the presence of HIV antibodies. * Reporting of medical problems, including information on unexpected hospitalizations and medications. If a participant has died, the study will document the cause of death and autopsy information if available.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • To provide a mechanism for adequate follow-up of subjects previously participating in gene transfer or other immunotherapy studies at the National Cancer Institute as required by the U.S. Food and Drug Administration. (on-going)
  • To facilitate the continuous usage of stored research specimens collected from subjects under completed and ongoing protocols. (on-going)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2004-09-13
Completion: Ongoing
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Jennifer L Marte (PRINCIPAL_INVESTIGATOR) - National Cancer Institute (NCI)
Contact Information
Study Contact:
Sheri A McMahon, R.N.
(240) 760-7968
sheri.mcmahon@nih.gov
Jennifer L Marte
(301) 496-7214
martej@mail.nih.gov
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
800-411-1222
ccopr@nih.gov
National Institutes of Health Clinical Center
Interventions
N/A
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: * Subjects who received poxviral vectors (vaccinia and/or fowlpox) or other vaccines utilizing gene transfer or any other immunotherapeutic agent through GMB, UOB and LTIB affiliated trials at the National Cancer Institute, as well as subjects at extramural sites receiving these agents as part of a multi-site trial. Available stored specimens obtained from NCI participants in GMB, UOB, and LTIB affiliated protocols may be transferred to this protocol for storage and eventual future research use. * Subjects must be \>= 18 years of age. EXCLUSION CRITERIA: Participants unwilling to participate. (Please note, participants may participate in this protocol and, at the same time, participate in an active treatment or continuing care study.)
Conditions Cancer, Advanced Cancer, Locally Advance...
Phase PHASE1
Enrollment 80
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AGX101 — Antibody Drug Conjugate

Primary Outcomes

  • Acceptable maximum tolerated dose for participants (21 days following the first dose of AGX101 (Day 1 through Day 21))
  • Number of participants with adverse events (Screening through end of treatment, approximately 6 months and up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-07-22
Completion: 2027-09-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Angiex, Inc.
Principal Investigators:
  • Glen Weiss, MD (STUDY_DIRECTOR) - Medical Lead
Contact Information
Study Contact:
Glen Weiss, MD
857-203-7808
trials@angiex.com
Diana Hanna, MD
USC/Norris Comprehensive Cancer Center
Nancy Olsen
941-377-9993
nolsen@flcancer.com
Florida Cancer Specialist
Interventions
  • Drug: AGX101 — Antibody Drug Conjugate
Study Locations (7 sites)
USC/Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Florida Cancer Specialist, Sarasota, Florida 34232 United States
Washington University School of Medicine, St Louis, Missouri 63110 United States
Sarah Cannon Research Center, Nashville, Tennessee 37203 United States
UT MD Anderson, Houston, Texas 77030 United States
NEXT Oncology, San Antonio, Texas 78229 United States
NEXT Oncology, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed unresectable, locally advanced, or metastatic solid tumors. * Refractory to or relapsed after all standard therapies known to provide proven clinical benefit, unless the patient is not a candidate for standard treatment, there is no standard treatment, or the patient refuses standard treatment after expressing an understanding of all available therapies with proven clinical benefit * Willing to authorize use of existing archival tissue, unless otherwise discussed with Sponsor * Time since the last dose of prior therapy to treat underlying malignancy (including other investigational therapy): Systemic cytotoxic chemotherapy: ≥ the duration of the most recent cycle of the previous regimen (with a minimum of 2 weeks for all, except 6 weeks for systemic nitrosourea or systemic mitomycin-C); Biologic therapy (eg, antibodies): ≥ 3 weeks; Small molecule therapies: ≥ 5 × half-life * Have an ECOG performance status of 0 to 1 * Have adequate organ function * LVEF ≥ 50%, as determined on cardiac ECHO or cardiac multiple-gated acquisition (MUGA) scan * Highly effective contraception for both male and female patients throughout the study Exclusion Criteria: * Colorectal cancer patients with an unresected primary colorectal tumor and non-small-cell lung cancer with predominant squamous histology (ie, squamous cell carcinoma of the lung) are excluded unless otherwise discussed and approved by Sponsor * Clinically unstable central nervous system (CNS) tumors or brain metastasis (stable and/or asymptomatic CNS metastases allowed) * Have not recovered to ≤ Grade 1 or baseline from all AEs due to previous therapies (patients with ≤ Grade 2 neuropathy, endocrine-related irAEs, or other AEs may be eligible after discussion with the Sponsor) * Has an active vasculitis that has required systemic treatment in the past 2 years prior to starting study treatment * Significant (ie, ≥ Grade 2) ocular disturbances * Variceal bleeding within 6 months prior to treatment, currently untreated or incompletely treated varices with bleeding, or who otherwise are at a high risk of bleeding * Any other concurrent antineoplastic treatment except for allowed local radiation of lesions for palliation (to be considered non-target lesions after treatment) and hormone ablation * Uncontrolled or life-threatening symptomatic concomitant disease, including known symptomatic HIV positive with an AIDS defining opportunistic infection within the last year, known symptomatic active hepatitis B or C, or known active tuberculosis * Has undergone a major surgery within 3 weeks prior to starting study treatment or has inadequate healing or recovery from complications of surgery prior to starting study treatment * Has received prior radiotherapy within 2 weeks prior to starting study treatment * Has or had a potentially life-threatening second malignancy requiring systemic treatment within the last 3 years, or which would impede evaluation of treatment response * Clinically significant cardiovascular disease * Patients on a potent CYP3A inhibitor or CPY3A inducer who cannot be changed to another medication * Has an active infection requiring concurrent systemic antibiotic therapy * A woman of child-bearing potential (WOCBP) who has a positive pregnancy test prior to treatment * Is breastfeeding or expecting to conceive or father children within the projected duration of the study
Conditions Triple-Negative Breast Cancer
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This open-label, prospective, single-arm clinical study aims to evaluate the efficacy and safety of pegfilgrastim in preventing febrile neutropenia (FN) among patients with triple-negative breast cancer (TNBC) receiving anthracycline/cyclophosphamide (AC) chemotherapy following neoadjuvant paclitaxel/carboplatin therapy. In the Keynote-522 regimen, paclitaxel and carboplatin are administered prior to the AC phase, which may increase cumulative myelosuppression and subsequently elevate the risk of FN during AC. Despite this clinical concern, real-world evidence supporting the prophylactic use of pegfilgrastim in Korean patients undergoing this regimen remains insufficient. A total of 40 adult TNBC patients will be enrolled. Pegfilgrastim 6 mg will be administered subcutaneously once per cycle on Day 2 of each AC cycle (Cycles 1-4), approximately 24 hours after chemotherapy completion. The primary objective is to assess the incidence of FN during the four AC cycles. Secondary objectives include hospitalization due to FN, incidence of Grade 4 neutropenia, delays or dose reductions in chemotherapy due to neutropenia, and evaluation of hematologic and non-hematologic toxicities. This study is descriptive in nature and does not involve hypothesis-testing sample size calculations. The sample size of 40 was determined based on feasible drug supply and is expected to provide clinically meaningful insight when compared with existing real-world data, in which the FN risk during AC without prophylactic G-CSF is historically reported at approximately 20-25%. The findings from this study may offer essential clinical evidence supporting the preventive use of pegfilgrastim during the AC phase in TNBC patients treated with the paclitaxel/carboplatin-leading neoadjuvant regimen.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Pegfilgrastim (Neulasta) — Pegfilgrastim 6 mg is administered subcutaneously once per cycle on Day 2 (approximately 24 ± 2 hours after completion of AC chemotherapy) for a total of four cycles (Cycle 1-4).

Primary Outcomes

  • Incidence of Febrile Neutropenia (FN) (Up to 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-28
Completion: 2026-10-27
Eligibility
Age: 19 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yonsei University
Principal Investigators:
  • Gun Min Kim, Professor (PRINCIPAL_INVESTIGATOR) - Severance Hospital
Contact Information
Study Contact:
Gun Min Kim, Professor
02-2228-8126
gmkim77@yuhs.ac
Gun Min Kim
02-2228-8126
gmkim77@yuhs.ac
Severance Hospital, Yonsei University Health System
Jee Hung KIM
+82 02-2019-3305
OK8504@yuhs.ac
Gangnam Severance Hospital, Yonsei University Health System
Interventions
  • Drug: Pegfilgrastim (Neulasta) — Pegfilgrastim 6 mg is administered subcutaneously once per cycle on Day 2 (approximately 24 ± 2 hours after completion of AC chemotherapy) for a total of four cycles (Cycle 1-4).
Study Locations (2 sites)
Severance Hospital, Yonsei University Health System, Seoul, Seodaemun-gu 03722 South Korea
Gangnam Severance Hospital, Yonsei University Health System, Seoul, 06273 South Korea
Eligibility Criteria
Inclusion Criteria: * 1\. Women diagnosed with triple-negative breast cancer by pathology or cytology. 2. Age ≥19 and ≤70 years. 3. ECOG performance status 0-1. 4. Stage II-III breast cancer confirmed pathologically or clinically. 5. Planned to receive AC chemotherapy following paclitaxel/carboplatin as neoadjuvant therapy. 6\. Adequate organ function: 1. Absolute neutrophil count (ANC) ≥1,000 cells/mm³ 2. Platelet count ≥75,000 cells/mm³ 3. Creatinine clearance ≥50 mL/min or serum creatinine \<1.5× ULN 4. Total bilirubin ≤1.5× ULN 5. AST ≤2.5× ULN 6. ALT ≤2.5× ULN 7. Ability to provide written informed consent and willingness to comply with study procedures. Exclusion Criteria: * 1\. Prior treatment with cytotoxic chemotherapy. 2. Prior treatment with G-CSF or pegylated G-CSF. 3. History of conditions that may affect bone marrow function (e.g., severe liver or kidney disease). 4\. Receipt of radiotherapy within 4 weeks prior to study initiation. 5. Active uncontrolled infection or inflammatory disease that may affect study outcomes. 6\. Receipt of blood transfusion within 60 days prior to study initiation. 7. Pregnant, breastfeeding, or unwilling to use appropriate contraception. 8. Any condition judged by the investigator to make the patient unsuitable for participation.